Vanguard Group Inc. Purchases 50,673 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Vanguard Group Inc. lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,865,115 shares of the company’s stock after acquiring an additional 50,673 shares during the period. Vanguard Group Inc. owned approximately 5.70% of TransMedics Group worth $147,214,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in TMDX. Mackenzie Financial Corp bought a new stake in shares of TransMedics Group in the 4th quarter worth $35,804,000. American Century Companies Inc. boosted its position in shares of TransMedics Group by 271.2% during the third quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock valued at $26,661,000 after buying an additional 355,755 shares during the last quarter. First Turn Management LLC bought a new stake in TransMedics Group in the 4th quarter worth about $25,509,000. First Light Asset Management LLC increased its holdings in TransMedics Group by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock worth $59,538,000 after buying an additional 136,217 shares in the last quarter. Finally, Lisanti Capital Growth LLC purchased a new position in TransMedics Group in the 4th quarter worth about $8,638,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $149.53 on Friday. The stock has a 50-day moving average price of $135.87 and a 200 day moving average price of $101.27. The stock has a market capitalization of $4.93 billion, a P/E ratio of -439.79 and a beta of 1.98. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $154.14. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The firm had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. During the same quarter last year, the business posted ($0.08) earnings per share. The company’s revenue for the quarter was up 132.9% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group, Inc. will post 0.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director David Weill sold 2,500 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $129.82, for a total transaction of $324,550.00. Following the completion of the transaction, the director now owns 11,193 shares in the company, valued at $1,453,075.26. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director David Weill sold 2,500 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $129.82, for a total transaction of $324,550.00. Following the sale, the director now directly owns 11,193 shares of the company’s stock, valued at approximately $1,453,075.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 15,512 shares of the firm’s stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $90.45, for a total transaction of $1,403,060.40. Following the completion of the transaction, the insider now directly owns 25,185 shares of the company’s stock, valued at $2,277,983.25. The disclosure for this sale can be found here. Insiders have sold a total of 270,554 shares of company stock worth $31,760,498 in the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on TMDX. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Oppenheimer lifted their target price on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. increased their price target on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Cantor Fitzgerald assumed coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective for the company. Finally, Piper Sandler reissued an “overweight” rating and issued a $120.00 target price on shares of TransMedics Group in a report on Friday, June 21st. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $133.88.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.